Literature DB >> 22459076

Experiences in fragment-based drug discovery.

Christopher W Murray1, Marcel L Verdonk, David C Rees.   

Abstract

Fragment-based drug discovery (FBDD) has become established in both industry and academia as an alternative approach to high-throughput screening for the generation of chemical leads for drug targets. In FBDD, specialised detection methods are used to identify small chemical compounds (fragments) that bind to the drug target, and structural biology is usually employed to establish their binding mode and to facilitate their optimisation. In this article, we present three recent and successful case histories in FBDD. We then re-examine the key concepts and challenges of FBDD with particular emphasis on recent literature and our own experience from a substantial number of FBDD applications. Our opinion is that careful application of FBDD is living up to its promise of delivering high quality leads with good physical properties and that in future many drug molecules will be derived from fragment-based approaches.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2012        PMID: 22459076     DOI: 10.1016/j.tips.2012.02.006

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  57 in total

1.  Detection of secondary binding sites in proteins using fragment screening.

Authors:  R Frederick Ludlow; Marcel L Verdonk; Harpreet K Saini; Ian J Tickle; Harren Jhoti
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-11       Impact factor: 11.205

2.  A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design.

Authors:  A J Kooistra; S Kuhne; I J P de Esch; R Leurs; C de Graaf
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

3.  Identifying ligand-binding hot spots in proteins using brominated fragments.

Authors:  Morten K Grøftehauge; Martin Ø Therkelsen; Rolf Taaning; Troels Skrydstrup; J Preben Morth; Poul Nissen
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-08-19

4.  The importance of molecular complexity in the design of screening libraries.

Authors:  Shahul H Nilar; Ngai Ling Ma; Thomas H Keller
Journal:  J Comput Aided Mol Des       Date:  2013-09       Impact factor: 3.686

Review 5.  Chemical predictive modelling to improve compound quality.

Authors:  John G Cumming; Andrew M Davis; Sorel Muresan; Markus Haeberlein; Hongming Chen
Journal:  Nat Rev Drug Discov       Date:  2013-12       Impact factor: 84.694

Review 6.  Evolutions in fragment-based drug design: the deconstruction-reconstruction approach.

Authors:  Haijun Chen; Xiaobin Zhou; Ailan Wang; Yunquan Zheng; Yu Gao; Jia Zhou
Journal:  Drug Discov Today       Date:  2014-09-27       Impact factor: 7.851

7.  Ligand deconstruction: Why some fragment binding positions are conserved and others are not.

Authors:  Dima Kozakov; David R Hall; Stefan Jehle; Sefan Jehle; Lingqi Luo; Stefan O Ochiana; Elizabeth V Jones; Michael Pollastri; Karen N Allen; Adrian Whitty; Sandor Vajda
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

Review 8.  Fragment-based inhibitor discovery against β-lactamase.

Authors:  Derek A Nichols; Adam R Renslo; Yu Chen
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

9.  In silico fragment-mapping method: a new tool for fragment-based/structure-based drug discovery.

Authors:  Noriyuki Yamaotsu; Shuichi Hirono
Journal:  J Comput Aided Mol Des       Date:  2018-09-08       Impact factor: 3.686

10.  Multiple fragment docking and linking in primary and secondary pockets of dopamine receptors.

Authors:  Márton Vass; Eva Agai-Csongor; Ferenc Horti; György M Keserű
Journal:  ACS Med Chem Lett       Date:  2014-07-10       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.